Table 5:
Pairwise comparisons between data recorded at baseline and at 6 months post-SGLT2i onset on an intention-to-treat basis stratified by SGLT2i prescribed.
| Characteristics | Baseline | 6 months of SGLT2i |
P-value baseline versus 6 months |
P-value,a,b SGLT2i |
|---|---|---|---|---|
| Body weight (kg), mean (95% CI) | .334 | |||
| Canagliflozin (n = 62) | 85.6 (81.4–90.0) | 83.2 (80.0–87.5) | <.001 | |
| Empagliflozin (n = 170) | 84.0 (80.4–86.6) | 81.8 (79.2–84.3) | <.001 | |
| Dapagliflozin (n = 76) | 81.4 (76.1–83.8) | 79.9 (76.1–83.8) | <.001 | |
| SBP (mmHg), mean (95% CI) | .650 | |||
| Canagliflozin (N = 62) | 137 (133–140) | 131 (127–135) | .01 | |
| Empagliflozin (m = 172) | 138 (136–141) | 133 (132–136) | .01 | |
| Dapagliflozin (N = 77) | 133 (130–137) | 130 (127–134) | .141 | |
| DPB (mmHg), mean (95% CI) | .993 | |||
| Canagliflozin (N = 62) | 75.9 (73.4–78.4) | 73.5 (71.1–76.0) | .034 | |
| Empagliflozin (n = 172) | 77.0 (75.5–78.5) | 74.7 (73.2–76.1) | .003 | |
| Dapagliflozin (n = 77) | 74.8 (72.5–77.0) | 72.6 (70.4–74.8) | .063 | |
| Haemoglobin (g/dl), mean (95% CI) | .318 | |||
| Canagliflozin (n = 60) | 13.8 (13.3–14.2) | 14.1 (13.7–14.5) | .021 | |
| Empagliflozin (N = 182) | 13.6 (13.3–13.8) | 14.0 (13.7–14.2) | <.001 | |
| Dapagliflozin (n = 76) | 13.3 (13.0–13.7) | 13.9 (13.6–14.3) | <.001 | |
| Fasting glycaemia (mg/dl), mean (95% CI) | .343 | |||
| Canagliflozin (n = 62) | 147 (136–158) | 129 (120–139) | .009 | |
| Empagliflozin (n = 187) | 149 (142–155) | 139 (134–145) | .002 | |
| Dapagliflozin (n = 78) | 149 (140–159) | 133 (124–141) | .001 | |
| HbA1c (%), mean (95% CI) | .075 | |||
| Canagliflozin (n = 56) | 7.50 (7.20–7.80) | 7.05 (6.75–7.35) | .002 | |
| Empagliflozin (n = 164) | 7.53 (7.35–7.70) | 7.32 (7.15–7.50) | .022 | |
| Dapagliflozin (n = 73) | 7.50 (7.24–7.76) | 6.96 (6.70–7.22) | <.001 | |
| eGFR (ml/min/1.73 m2), mean (95% CI) | .607 | |||
| Canagliflozin (n = 62) | 58.5 (53.5–63.4 | 55.4 (50.3–60.6) | .027 | |
| Empagliflozin (n = 187) | 59.1 (56.2–62.0) | 57.4 (54.4–60.3) | .032 | |
| Dapagliflozin (n = 77) | 55.9 (51.4–60.4) | 54.5 (49.8–59.1) | .088 | |
| Total cholesterol (mg/dl), mean (95% CI) | .794 | |||
| Canagliflozin (n = 60) | 167 (158–177) | 162 (153–171) | .241 | |
| Empagliflozin (n = 170) | 155 (149–160) | 151 (145–156) | .075 | |
| Dapagliflozin (n = 74) | 158 (150–166) | 156 (148–164) | .647 | |
| HDL cholesterol (mg/dl), mean (95% CI) | .565 | |||
| Canagliflozin (n = 47) | 46.7 (42.3–51.1) | 47.0 (42.4–51.6) | .809 | |
| Empagliflozin (n = 149) | 45.4 (42.9–47.8) | 45.3 (42.7–47.9) | .900 | |
| Dapagliflozin (n = 71) | 48.1 (44.5–51.7) | 46.9 (43.2–50.7) | .202 | |
| Triglycerides (mg/dl), median (IQR) | .654 | |||
| Canagliflozin (n = 54) | 174 (149–200) | 172 (145–199) | .779 | |
| Empagliflozin (n = 167) | 178 (164–193) | 180 (165–199) | .742 | |
| Dapagliflozin (n = 73) | 180 (158–202) | 189 (166–213) | .242 | |
| Serum uric acid (mg/dl), mean (95% CI) | .908 | |||
| Canagliflozin (n = 52) | 6.08 (5.68–6.49) | 5.93 (5.54–6.32) | .397 | |
| Empagliflozin (n = 157) | 6.32 (6.09–6.55) | 5.87 (5.65–6.91) | <.001 | |
| Dapagliflozin (n = 72) | 6.29 (5.94–6.63) | 5.82 (5.49–6.15) | .001 | |
| Serum magnesium (mg/dl), mean (95% CI) | .839 | |||
| Canagliflozin (n = 22) | 1.61 (1.50–1.72) | 1.74 (1.63–1.85) | .001 | |
| Empagliflozin (n = 130) | 1.61 (1.56–1.65) | 1.75 (1.71–1.80) | <.001 | |
| Dapagliflozin (n = 76) | 1.64 (1.57–1.71 | 1.80 (1.73–1.87) | <.001 | |
| UPCR (mg/g), median (IQR) | .222 | |||
| Canagliflozin (n = 47) | 140 (80–345) | 130 (70–249) | .056 | |
| Empagliflozin (n = 128) | 174 (75–426) | 160 (77–348) | .027 | |
| Dapagliflozin (n = 54) | 198 (95–618) | 185 (98–490) | .100 | |
| Baseline UPCR <300 mg/g, median (IQR) | .386 | |||
| Canagliflozin (n = 35) | 100 (68–170) | 110 (66–170) | .815 | |
| Empagliflozin (n = 87) | 101 (51–178) | 110 (59–210) | .293 | |
| Dapagliflozin (n = 34) | 112 (70–171) | 113 (72–183) | .241 | |
| Baseline UPC ≥300 mg/g, median (IQR) | .072 | |||
| Canagliflozin (n = 12) | 1680 (447–3945) | 602 (275–2350) | .028 | |
| Empagliflozin (n = 41) | 709 (430–1423) | 520 (273–919) | <.001 | |
| Dapagliflozin (n = 20) | 820 (524–1334) | 699 (411–1093) | .006 | |
| UAC (mg/g), median (IQR) | .900 | |||
| Canagliflozin (n = 42) | 90 (14–163) | 50 (10–175) | .037 | |
| Empagliflozin (n = 38) | 77 (20–215) | 41 (12–151) | .054 | |
| Dapagliflozin (n = 27) | 82 (28–360) | 50 (10–210) | .091 |
SBP, systolic blood pressure; DBP, dyastolic blood pressure.
a
For parametric data, P-values were calculated in a repeated measures general linear model.
b
For non-parametric data, P-values were calculated on log-transformed values and these were then adjusted by age and sex.